Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 4 studies | 23% ± 4% |
Insufficient scRNA-seq data for expression of UGT2B15 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 99% | 6244.04 | 223 / 226 | 94% | 325.41 | 382 / 406 |
pancreas | 92% | 641.11 | 302 / 328 | 72% | 36.09 | 129 / 178 |
stomach | 73% | 1008.27 | 262 / 359 | 39% | 6.66 | 111 / 286 |
intestine | 41% | 747.79 | 400 / 966 | 47% | 8.71 | 250 / 527 |
bladder | 10% | 22.05 | 2 / 21 | 26% | 7.89 | 133 / 504 |
breast | 5% | 20.83 | 22 / 459 | 24% | 4.18 | 272 / 1118 |
lymph node | 0% | 0 | 0 / 0 | 17% | 1.00 | 5 / 29 |
esophagus | 0% | 2.99 | 6 / 1445 | 16% | 5.10 | 29 / 183 |
prostate | 1% | 1.40 | 2 / 245 | 13% | 2.74 | 64 / 502 |
peripheral blood | 12% | 28.20 | 115 / 929 | 0% | 0 | 0 / 0 |
lung | 0% | 0.16 | 1 / 578 | 12% | 3.92 | 139 / 1155 |
uterus | 0% | 0 | 0 / 170 | 3% | 0.82 | 13 / 459 |
ovary | 0% | 0 | 0 / 180 | 2% | 0.15 | 9 / 430 |
spleen | 0% | 4.06 | 1 / 241 | 0% | 0 | 0 / 0 |
kidney | 0% | 0 | 0 / 89 | 0% | 0.36 | 3 / 901 |
skin | 0% | 0.06 | 1 / 1809 | 0% | 0.01 | 1 / 472 |
adipose | 0% | 0.80 | 3 / 1204 | 0% | 0 | 0 / 0 |
heart | 0% | 0.17 | 1 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 0.07 | 1 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
adrenal gland | 0% | 0 | 0 / 258 | 0% | 0 | 0 / 230 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
brain | 0% | 0 | 0 / 2642 | 0% | 0 | 0 / 705 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
thymus | 0% | 0 | 0 / 653 | 0% | 0 | 0 / 605 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0008202 | Biological process | steroid metabolic process |
GO_0052695 | Biological process | cellular glucuronidation |
GO_0008210 | Biological process | estrogen metabolic process |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0015020 | Molecular function | glucuronosyltransferase activity |
GO_0001972 | Molecular function | retinoic acid binding |
Gene name | UGT2B15 |
Protein name | UDP-glucuronosyltransferase 2B15 (UDPGT 2B15) (UGT2B15) (EC 2.4.1.17) (HLUG4) (UDP-glucuronosyltransferase 2B8) (UDPGT 2B8) (UDPGTh-3) UDP-glucuronosyltransferase UGT2B15 UDP-glucuronosyltransferase (EC 2.4.1.17) |
Synonyms | UGT2B8 |
Description | FUNCTION: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile . Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds . Catalyzes the glucuronidation of endogenous steroid hormones such as androgens (testosterone, androsterone) and estrogens (estradiol, epiestradiol, estriol, catechol estrogens) . Displays glucuronidation activity toward several classes of xenobiotic substrates, including phenolic compounds (eugenol, 4-nitrophenol, 4-hydroxybiphenyl) and phenylpropanoids (naringenin, coumarins) . Catalyzes the glucuronidation of monoterpenoid alcohols such as borneol, menthol and isomenthol, a class of natural compounds used in essential oils (By similarity). . |
Accessions | Q9UHH3 P54855 A0A0G2JMZ5 ENST00000611777.2 ENST00000338206.6 |